Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial

Kimura, Tomokazu; Ishikawa, Hitoshi; Nagumo, Yoshiyuki; Sekino, Yuta; Kageyama, Yukio; Ushijima, Hiroki; Kawai, Taketo; Yamashita, Hideomi; Azuma, Haruhito; Nihei, Keiji; Takemura, Masae; Hashimoto, Koichi; Maruo, Kazushi; Tsuzuki, Toyonori; Nishiyama, Hiroyuki

doi:10.1016/j.ijrobp.2023.05.013

Cited by 10 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This combination was focused on grades T2–T3 cancer (16.2 Gy to the whole bladder and 41.4 Gy component to the smaller pelvic field) and atezolizumab to the patient at 3-week intervals. Compared to monotherapy, this combination demonstrated high pathological complete response (pCR) rates for high-risk patients (older patients and those having a higher expression of PD-L1) [ 18 ]. In patients with locally advanced/metastatic UC, the combination of atezolizumab with front-line platinum-based chemotherapy (using the chemotherapy agents gemcitabine and cisplatin or carboplatin) showed a potentially improved median PFS (8.2 months).…”

Section: Introductionmentioning

confidence: 99%

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer

Sabaté Ortega,

Fort Culillas,

Escoda Garcia

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Cutaneous immune-related adverse events (cirAEs) are the most common side effects of immune checkpoint inhibitor (ICI) therapy (30–50% for all grades). The vast majority of them are low or mild and can be treated without ICI interruption. Autoimmune blistering disorders, such as immune-mediated bullous pemphigoid (IBP), are rare (<1%) but potentially serious conditions that must be early detected. The onset generally occurs within the first months of the treatment, and it appears to be more common with antiprogrammed death-1 or antiprogrammed ligand 1 (anti-PD1/PDL1) than with anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4). We present a case of a three-day severe IBP onset after receiving the first cycle of atezolizumab. This exceptional early presentation could suggest the presence of some predisposing condition and demonstrates the need to better understand predictive toxicity-related biomarkers in candidate patients for immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer

Sabaté Ortega,

Fort Culillas,

Escoda Garcia

et al. 2023

Current Oncology

View full text Add to dashboard Cite

show abstract

Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer

Swinton,

Devi,

Song

et al. 2024

World J Urol

View full text Add to dashboard Cite

Over the last two to three decades the non-surgical curative management of bladder cancer has significantly progressed. Increasing evidence supports the use of bladder preservation as an alternative to radical cystectomy (RC) for localised muscle-invasive bladder cancer (MIBC). Radiosensitisation with chemotherapy or hypoxia modification improves the efficacy of radiotherapy. Systemic treatments play an important role in the management of localised MIBC with the benefit of neoadjuvant chemotherapy prior to radical treatment well established. The use of immune checkpoint inhibitors (ICIs) in the radical treatment of bladder cancer, their safe combination with radical radiotherapy regimens and whether the addition of ICIs improve rates of cure are outstanding questions beginning to be answered by ongoing clinical trials. In this narrative review, we discuss the current evidence for bladder preservation and the role of systemic treatments for localised MIBC.

show abstract

Terapia trimodal para el cáncer de vejiga: ¿es ahora el estándar para la enfermedad músculo-invasiva?

López Valcárcel,

Barrado Los Arcos,

Ferri Molina

et al. 2024

Actas Urológicas Españolas

View full text Add to dashboard Cite

Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial

Cited by 10 publications

References 49 publications

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer

Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer

Terapia trimodal para el cáncer de vejiga: ¿es ahora el estándar para la enfermedad músculo-invasiva?

Contact Info

Product

Resources

About